-
Grid cell networks are impaired in a mouse model of early Alzheimer's disease
Time of Update: 2022-05-23
In a J20 transgenic mouse model of familial AD, coding impairment of the MEC grid cell network that overexpresses aβ in the hippocampus and entorhinal cortex .
-
Nat Aging: Cell regeneration therapy can safely reverse aging in mice
Time of Update: 2022-05-23
"We are delighted that we can use this approach to slow aging in normal animals throughout the lifespan," said co-corresponding author Professor Juan Carlos Izpisua Belmonte of the Gene Expression Laboratory at the Salk Institute for Biological Studies .
-
Nat Genet: Delaying DNA replication fork speeds leads to cell fate changes and enhances cell reprogramming efficiency
Time of Update: 2022-05-23
The relevant research results were published online in the journal Nature Genetics on March 7, 2022, with the title of "DNA replication fork speed underlies cell fate changes and promotes reprogramming" .
-
Sci Adv: Scientists hope to develop novel therapy for small cell lung cancer
Time of Update: 2022-05-23
of the EP300 KIX domain in the treatment of novel therapeutic interventions . (Bioon. com)>Original source:>KEE-BEOM KIM, ASHISH
-
Cell and gene therapy represented by CAR-T therapy has become a prairie prairie
Time of Update: 2022-05-23
? Standardized development stage (2016-present) In 2017, the State Food and Drug Administration promulgated the "Technical Guidelines for Research and Evaluation of Cell Therapy Products (Trial)", which proposed the safety, Valid, quality-controllable general technical requirements .
-
with chemotherapy for the neoadjuvant treatment of selected adult patients with resectable non-small cell lung cancer
Time of Update: 2022-05-23
immune-mediated adverse reactions, including pneumonitis, colitis, hepatitis or hepatotoxicity, endocrinopathy, cutaneous adverse reactions, nephritis with renal insufficiency, and other immune-mediated adverse reactions adverse reactions; infusion
-
with chemotherapy significantly improved event-free survival in patients with non-small cell lung cancer
Time of Update: 2022-05-23
CheckMate -816 is the first phase III clinical study to demonstrate that an immune-based combination therapy can significantly improve EFS and pathological complete response (pCR) rates in patients with non-small cell lung cancer in the neoadjuvant phase .
-
Aging Cell: Scientists Reveal Perredoxin 3 Can Clear Mitochondrial Hydrogen Peroxide To Treat Muscle Atrophy
Time of Update: 2022-05-23
13569Recently, researchers from the Oklahoma Medical Research Foundation published a paper entitled "Scavenging mitochondrial hydrogen peroxide by peroxiredoxin 3 overexpression attenuates contractile dysfunction and muscle atrophy in a murine model of accelerated sarcopenia" in the journal "Aging Cell".
-
Leukemia: Efficacy and Safety of Guadecitabine in Patients with Peripheral T-Cell Lymphoma
Time of Update: 2022-05-22
RHOAG17V mutation is associated with prolonged progression-free survivalIn conclusion, Guadecitabine demonstrated acceptable overall response rates and toxicity profiles in patients with peripheral T-cell lymphoma ; decitabine analogs may be promising candidates for future combined targeting of histone methyltransferases.
-
Tumours are full of tricks, but bypass the sniper immune cell combination therapy to kill the tumor with a two-pronged approach
Time of Update: 2022-05-22
In a mouse model of ovarian cancer, the researchers used both EPA and purinoceptor antagonists, and the results greatly increased the proliferation of T cells, restoring their ability to kill tumors .
-
New research in the sub-journal of Nature reveals the regulatory mechanism of hematopoietic stem cells entering the bone marrow for the first time
Time of Update: 2022-05-22
▲The huge difference between hematopoietic stem cells and bone marrow microenvironment between embryonic and adulthood (Image source: Reference [1])The experimental results revealed that the bone artery is the key microenvironmental cell in the embryonic stage .
-
"Cell" important breakthrough!
Time of Update: 2022-05-22
ways, and can even transmit specific signals to the brain through the gastrointestinal vagus nerve . In the field of oncology, microorganisms are also one of the objects that scientists focus
-
BeiGene's Tislelizumab Approved for the Eighth Indication for Esophageal Squamous Cell Carcinoma
Time of Update: 2022-05-22
Screenshot source: NMPA official websiteTislelizumab is a humanized IgG4 anti-programmed death 1 (PD-1) monoclonal antibody designed to minimize binding to Fcγ receptors in macrophages .
-
The protective shield of cancer cells must be broken!
Time of Update: 2022-05-21
According to new research in the Proceedings of the National Academy of Sciences (PNAS), for immunotherapy to really work, it is necessary to address the protective environment that cancer cells create for themselves .
-
Junshi Bio's Toripalimab for the Treatment of Small Cell Lung Cancer Receives Orphan Drug Designation by the U.S. FDA
Time of Update: 2022-05-21
>will help toripalimab enjoy certain policy support in the follow-up research and development, registration and commercialization of toripalimab in the United States , including but not limited to (1) taxation
-
Bmc Infect Dis: Systemic Antifungal Strategies in Allogeneic Hematopoietic Stem Cell Recipients: Analysis of a Cross-sectional Observational AFHEM Study
Time of Update: 2022-05-21
The literature reported here analyzes a cross-sectional observational AFHEM study to describe the use of antifungal drugs in real-world clinical practice in alloHSCT recipients hospitalized in a French hematology ward .
-
Bispecific antibody epcoritamab yields positive results in LBCL, including in patients who have failed CAR-T cell therapy
Time of Update: 2022-05-21
Biopharmaceutical companies AbbVie and Genmab today announced updated results from a Phase I/II trial evaluating the bispecific antibody epcoritamab in patients with relapsed/refractory large B-cell lymphoma (LBCL).
-
J Clin Oncol: Efficacy and safety of nasoprilumab in the treatment of hematopoietic stem cell transplantation-associated thrombotic microangiopathy
Time of Update: 2022-05-21
This study is a single-arm, open-label, flight trial to evaluate the safety and efficacy of nasoprilumab in adult patients with HSCT-TMA .
-
Junshi Bio's Toripalimab in the Treatment of Small Cell Lung Cancer Receives FDA Orphan Drug Designation
Time of Update: 2022-05-21
On April 13, Toripalimab, an anti-PD-1 monoclonal antibody independently developed by Junshi Bio for the treatment of small cell lung cancer (SCLC), was granted orphan drug designation by the U.
-
Nature Reviews Drug Discovery: Using NK Cells for Cancer Immunotherapy
Time of Update: 2022-05-21
Bispecific or specific antibodiesBispecific or specific antibodiesBispecific or trispecific antibodies can simultaneously bind to NK cell-activated receptors and tumor antigens, promoting more potent and durable NK-mediated cytotoxicity .
